Important Safety Information

Prescribe Keveyis

The Proven Leader for Primary Periodic Paralysis Treatment

KEVEYIS® (dichlorphenamide) is a daily pill proven to treat and reduce Primary Periodic Paralysis (PPP) attack frequency, severity and duration.1,2
See the data

KEVEYIS® (dichlorphenamide) is proven to treat PPP1

KEVEYIS can help patients gain greater control over Primary Periodic Paralysis (PPP). It’s proven to reduce the frequency, severity and duration of attacks.1,2

When compared with a placebo in a 9-week study1,2:

  • PPP episodes decreased
    Patients taking KEVEYIS had fewer episodes.
  • PPP episodes were shorter
    When patients taking KEVEYIS did have episodes, they didn’t last as long.
  • PPP episodes were not as severe
    Patients taking KEVEYIS reported that their episodes were not as severe.
Learn more about KEVEYIS

“I went from about one [attack] a week to one a month since starting KEVEYIS.”

Paul, KEVEYIS Patient and PPP Mentor

GET SUPPORT

What is PPP?

PPP is a genetic condition that can be progressive and debilitating.3,4 It involves a group of rare channelopathies that manifest as recurrent attacks of muscle weakness or temporary paralysis often precipitated by triggers.
Learn more about PPP

Ensuring you and your PPP patients never walk alone

Managing PPP takes more than dichlorphenamide alone. Our Xeris CareConnection™ experts have been supporting the PPP community since 2016. We’re ready to help your office and patients every step of the way. Here’s what makes us the proven leader for PPP:
  • Patient Access Managers
    These PPP experts provide guidance in managing critical aspects of your patient’s treatment journey — from help navigating insurance coverage and pharmacy guidance to PPP education.
  • Insurance and pharmacy support
    • Our team of experts help patients and providers navigate insurance coverage.
    • We provide access to a PANTHERx pharmacist who specializes in KEVEYIS and can guide patients through therapy.
Explore support resources

“I assumed my first call with my PAM was only for educational purposes, but after I talked to him, I realized how much better I was feeling emotionally, just being able to have contact with someone who understood what I was going through.”

Dennis, KEVEYIS patient and PPP Mentor

PATIENT TESTIMONIALS

Real KEVEYIS patients share their stories

Hear from patients who gained greater control over PPP.

Paul
On KEVEYIS since 2017
“I went from about one [attack] a week to one a month since starting KEVEYIS.”

Paul
KEVEYIS patient
Hear more about Paul ➞
Kirsten
On KEVEYIS since 2016
“After starting KEVEYIS I have no attacks of full body paralysis.”

Kirsten
KEVEYIS patient
Hear more about Kirsten ➞
Dennis
On KEVEYIS since 2016
“Before KEVEYIS, I was having a lot of episodes…it was horrible. [After starting KEVEYIS], I haven’t had a serious attack in years.”

Dennis
KEVEYIS patient
Hear more about Dennis ➞
Janine
On KEVEYIS since 2016
“Having more control over my symptoms on KEVEYIS I feel more confident, more independent.”

Janine
KEVEYIS patient
Hear more about Janine ➞
Explore patient stories
Take the next step

Get expert
support for you
and your patients

Simply complete the form and a KEVEYIS representative will be in touch.

References

  1. KEVEYIS [package insert]. Chicago, IL; Xeris Pharmaceuticals.
  2. Sansone VA, Burge J, McDermott MP, et al; for the Muscle Study Group. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology. 2016;86:1408-1416.
  3. Charles G, Zheng C, Lehmann-Horn F, Jurkat-Rott K, Levitt J. Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. J Neurol. 2013;260:2606-2613.
  4. Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients. Acta Myol. 2012;31:126–133.

INDICATION AND IMPORTANT SAFETY INFORMATION — READ MORE

Indication and Important Safety Information

 

Indication

KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

 

Important Safety Information

Contraindications

  • Hypersensitivity to dichlorphenamide or other sulfonamides
  • Concomitant use of KEVEYIS and high-dose aspirin
  • Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS
  • Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy

 

Warnings and Precautions

Hypersensitivity and Other Life-Threatening Reactions

  • Fatalities associated with the administration of sulfonamides have occurred because of adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias.
  • Pulmonary involvement can occur in isolation or as part of a systemic reaction.
  • Discontinue KEVEYIS at the first appearance of skin rash or any sign of immune-mediated or other life-threatening adverse reaction.

 

Concomitant Use of Aspirin or Other Salicylates

  • Carbonic anhydrous inhibitors, including KEVEYIS, can cause metabolic acidosis, which can increase the risk of salicylate toxicity.
  • Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin.
  • Concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Use with caution and carefully monitor in patients receiving low-dose aspirin.

 

Hypokalemia

  • KEVEYIS increases potassium excretion and can cause hypokalemia.
  • The risk of hypokalemia is greater when KEVEYIS is used in patients with conditions associated with hypokalemia (e.g., adrenocortical excess, renal tubular acidosis type 1 and 2), and in patients receiving other drugs that may cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillin, and theophylline).
  • Baseline and periodic measurements of serum potassium are recommended.
  • If hypokalemia develops or persists, consider reducing the dose or discontinuing KEVEYIS and correction of potassium levels.

 

Metabolic Acidosis

  • KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis.
  • Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may increase the severity of acidosis.
  • Concomitant use of KEVEYIS in compensated patients with respiratory acidosis, such as in advanced lung diseases, may lead to respiratory decompensation.
  • Baseline and periodic measurements of serum bicarbonate during KEVEYIS treatment are recommended.
  • If metabolic acidosis develops or persists, consider reducing the dose or discontinuing KEVEYIS.

 

Falls

  • KEVEYIS increases the risk of falls; risk is greater in the elderly and with higher doses.
  • Consider dose reduction or discontinuation of KEVEYIS in patients who experience falls while treated with KEVEYIS.

 

Pregnancy and Lactation

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known in humans whether dichlorphenamide is excreted in human milk; exercise caution when administered to a nursing woman.

Adverse Reactions

The most common adverse reactions seen in clinical trials (incidence ≥ 10% and greater than placebo) include paresthesias, cognitive disorder, dysgeusia, and confusional state.

Please see Full Prescribing Information.

Xeris

Keveyis®, Xeris Pharmaceuticals®, Xeris CareConnection™, and their associated logos are trademarks owned by or licensed to Xeris Pharmaceuticals, Inc.

FOR HEALTHCARE PROVIDERS

OTHER

Copyright © 2024 Xeris Pharmaceuticals, Inc. All rights reserved.
US-KEV-24-00042 7/2024

Find answers

Take the next step

Get customized support for your KEVEYIS journey. Simply fill out the information and a Patient Access Manager will contact you. They will walk you through the entire process, from diagnosis to treatment and beyond.

Please verify that you are a U.S. Healthcare Professional

I am NOT a U.S. Healthcare Professional

Got to KEVEYIS.com

I am a U.S. Healthcare Professional

Continue